Furthermore, HLA-A24 specific peptides of HER2/neu (15), tyrosinase in melanoma (16), CEA and MAGE-3 in gastrointestinal malignancies (17,18), SART-1 in oral squamous cell carcinoma (19), MUC5AC in pancreatic cancer (35), Eras in gastric cancer (36) and P53 in bladder cancer (20,21) had previously been used. This evidence concerns the gene ERBB2 and urinary bladder cancer.